Pam Taub, MD, FACC, FASPC

Dr Taub, Dr Patel, and Dr Kohli look ahead to the future of the management of cardiovascular risk and hyperlipidemia

Cardiologists discuss how to select the right treatment for your patient with hyperlipidemia

Expert cardiologists discuss the recent clinical trials results of the CLEAR-OUTCOMES trial and thee sub analysis on the inflammatory marker hcCRP.

Dr Kohli gives an overview of the mechanisms of action of non-statin agents for the management of hyperlipidemia.

Expert cardiologists discuss the cumulative burden of an elevated cholesterol over time.

Dr Taub describes effective strategies in overcoming access barriers to novel lipid lowering therapies.

Expert cardiologists describe the importance of combination therapy for hyperlipidemia in high risk patients

Dr Taub and Dr Patel discuss which non statin agents are available for LDL-C lowering.

Expert cardiologists discuss if there is such a thing as an LDL that is a too low.

Dr Taub discusses how to match the intensity of lipid lowering therapy to the assessed cardiovascular risk.

Dr Taub and Dr Patel discuss how to assess for cardiovascular risk in your patients.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky offer key takeaways in the management of hypercholesterolemia and ASCVD.

An expert panel discusses challenges and provides solutions to managing patients with hypercholesterolemia.

Our panel highlights the importance of a team-based approach to care in the management of hypercholesterolemia.

Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; provide an overview of upcoming treatment options for managing hypercholesterolemia.

Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; share benefits of combination therapy for lipid lowering in ASCVD and hypercholesterolemia.

A panel of experts discusses recommendations for managing statin intolerance in patients with hypercholesterolemia.

Pam Taub, MD, FACC, FASPC, shares her thoughts on use of coronary artery calcium (CAC) scores when treating patients with nonstatin therapies.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky review guidelines and recommendations for using lipid-lowering agents in addition to statins.

An expert panel reviews less frequently used lipid-lowering agents in hypercholesterolemia.

A panel of experts discusses use of bempedoic acid to manage hypercholesterolemia and data with bempedoic acid in combination with other lipid-lowering agents.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of ezetimibe and PCSK9 targeting agents for lipid lowering.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of statins in managing hypercholesterolemia based on varying levels of risk.

Alison Bailey, MD, FACC, reviews real-word data about LDL-C control and achievement of goals.

A panel of experts discuss the importance of achieving low-density lipoprotein cholesterol (LDL-C) in patients.

Experts in cardiology share their thoughts on patient/clinician communication and treatment customized to the individual patient.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky discuss the impact of lipid lowering on the risk of ASCVD.

A panel of experts comments on the importance of risk assessment in ASCVD as well as factors that contribute to risks.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, provide an overview of the prevalence of atherosclerotic cardiovascular diseases (ASCVD) and hypercholesterolemia in the development of ASCVD.